Table 1 Characteristics of the 180 chronic hepatitis B patients with or without hepatic fibrosis.

Characteristic	F0	F1–2	F3–4	F5–6
n	15	55	68	42
Mean age, years	31 ± 10	35 ± 10	34 ± 12	38 ± 14
Male/Female, n	7/8	28/27	36/32	24/18
WBC, ×10⁹/L	6.82 ± 1.44	6.26 ± 1.52	6.38 ± 1.67	6.20 ± 2.14
PLT, ×10⁹/L	224 ± 43	159 ± 45^a	156 ± 40^a	127 ± 33^abc
Albumin, g/L	42.61 ± 4.20	40.69 ± 4.81	40.81 ± 4.82	37.61 ± 4.16^abc
Serum ALT, U/L	49 ± 23	97 ± 38^a	124 ± 42^ab	118 ± 55^ab
Serum AST, U/L	47 ± 18	83 ± 33^a	81 ± 39^a	93 ± 38^a
Serum TBil, μM	15.57 ± 4.29	15.94 ± 5.23	18.52 ± 5.94^b	25.55 ± 6.15^abc
PT, s	11.02 ± 0.42	11.87 ± 0.83^a	12.17 ± 0.90^a	12.33 ± 1.22^a
PTA, %	133.10 ± 17.20	114.52 ± 16.24^a	109.69 ± 15.82^a	100.83 ± 15.69^abc
INR	0.82 ± 0.09	0.93 ± 0.12^a	0.95 ± 0.12^a	1.05 ± 0.15^abc
HBV DNA, Log₁₀ cp/mL	6.32 ± 0.36	6.11 ± 0.89	5.85 ± 1.02	5.96 ± 0.80
HBeAg, + /−(n)	12/3	35/20	35/33^a	18/24^ab
Serum HBsAg, IU/mL	7325 ± 2546	5102 ± 2810^a	5277 ± 2957^a	2438 ± 1776^abc

WBC, white blood cell; PLT, platelets; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBil, serum total bilirubin; PT, prothrombin time; PTA, prothrombinase activity; INR, international normalized ratio; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen.
^aDiffers from the F0 group, P < 0.05; ^bDiffers from the F1–2 group, P < 0.05; ^cDiffers from the F3–4 group, P < 0.05.

Quick links

Search